Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Murad Acne Complex Ads, ERSP Draws Line Between "Clear" And "Clears"

This article was originally published in The Tan Sheet

Executive Summary

Murad should change the "Get Clear In Four Weeks” claim for Murad Acne Complex to align more closely with FDA’s language and intent in the OTC acne product monograph, according to an industry self-regulation group.

You may also be interested in...



Stiefel's MaxClarity "More Medicine," Severe Acne Claims Irritate Competitor

Stiefel Laboratories' claims suggesting its MaxClarity foam-based system can treat severe acne by delivering more medicine than alternative products and without irritation did not sit well with the competition

Murad Implied Claims Should Be Modified While Acne Claims Are Supported

Murad should not imply Acne Skin Complex treats all causes of skin breakouts in direct advertising, according to the Council of Better Business Bureaus' Electronic Retailing Self-Regulation Program. ERSP issued the recommendation Feb. 16 on the National Advertising Review Council Web site after reviewing a 30-minute infomercial for the anti-acne system

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel